JOE vs PFE
JOE: A real estate developer and asset manager primarily focused on the growth and transformation of master-planned communities in Northwest Florida. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | JOE | PFE | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $67.38 | $26.20 | |
| Market cap as of 2026-08-08 | $3.8B | $149.3B | |
| P/E as of 2026-08-08 | 31.31 | 34.82 | JOE lower |
| PEG as of 2026-08-08 | 0.62 | -2.72 | PFE lower |
| Net margin as of 2026-08-08 | +22.5% | +6.8% | JOE higher |
| Gross margin as of 2026-08-08 | +44.0% | +74.7% | PFE higher |
| Operating margin as of 2026-08-08 | +30.2% | +6.8% | JOE higher |
| ROE as of 2026-08-08 | +16.1% | +4.9% | JOE higher |
| ROA as of 2026-08-08 | +8.1% | +2.1% | JOE higher |
| Debt / equity as of 2026-08-08 | 0.72 | 0.74 | JOE lower |
| Revenue growth (YoY) as of 2026-08-08 | +28.4% | -0.2% | JOE higher |
| Revenue CAGR (3y) SEC XBRL | +26.7% | -14.8% | JOE higher |
| Dividend yield as of 2026-08-08 | +0.9% | +6.6% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-08 | 1.30 | 0.27 | |
| 1-year return as of 2026-08-06 close | +33.9% | +9.5% | JOE higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.